BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that patient-reported health outcomes data for OTEZLA® (apremilast) were presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. The analyses from the phase III ESTEEM clinical trial program assessed the effect of apremilast on health-related quality of life measures and on work productivity/work limitation. Apremilast is the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), for patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Help employers find you! Check out all the jobs and post your resume.
